Real‐World Analysis of Guideline‐Based Therapy After Hospitalization for Heart Failure
Open Access
- 18 August 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 9 (16)
- https://doi.org/10.1161/jaha.119.015042
Abstract
Background Patients hospitalized with heart failure (HF) with reduced ejection fraction have high risk of rehospitalization or death. Despite guideline recommendations based on high‐quality evidence, a substantial proportion of patients with HF with reduced ejection fraction receive suboptimal care and/or do not comply with optimal care following hospitalization. Methods and Results This retrospective observational study identified 17 106 patients with HF with reduced ejection fraction with an incident HF‐related hospitalization using the Humana Medicare Advantage database (2008–2016). HF medication classes (beta‐blockers, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, or mineralocorticoid receptor antagonists) received in the year after hospitalization were recorded, and categorized by treatment intensity (ie, number of concomitant medication classes received: none [23% of patients; n=3987], monotherapy [22%; n=3777], dual therapy [41%; n=7056], or triple therapy [13%; n=2286]). Compared with no medication, risk of primary outcome (composite of death or rehospitalization) was significantly reduced (hazard ratio [95% CI]) with monotherapy (0.68 [0.64–0.71]), dual therapy (0.56 [0.53–0.59]), and triple therapy (0.45 [0.41–0.50]). Nearly half (46%) of patients who received post‐discharge medication had no dose escalation. Overall, 59% of patients had follow‐up with a primary care physician within 14 days of discharge, and 23% had follow‐up with a cardiologist. Conclusions In real‐world clinical practice, increasing treatment intensity reduced risk of death and rehospitalization among patients hospitalized for HF, though the use of guideline‐recommended dual and triple HF therapy remained low. There are opportunities to improve post‐discharge medical management for patients with HF with reduced ejection fraction such as optimizing dose titration and improving post‐discharge follow‐up with providers.Keywords
This publication has 34 references indexed in Scilit:
- Incremental Reduction in Risk of Death Associated With Use of Guideline‐Recommended Therapies in Patients With Heart Failure: A Nested Case‐Control Analysis of IMPROVE HFJournal of the American Heart Association, 2012
- Potential impact of optimal implementation of evidence-based heart failure therapies on mortalityAmerican Heart Journal, 2011
- Validity of claims‐based definitions of left ventricular systolic dysfunction in Medicare patientsPharmacoepidemiology and Drug Safety, 2011
- Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006JAMA, 2010
- Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failureAmerican Heart Journal, 2009
- Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and ReadmissionCirculation: Cardiovascular Quality and Outcomes, 2009
- Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and designAmerican Heart Journal, 2004
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital dischargeJournal of the American College of Cardiology, 2004
- Long-Term Trends in the Incidence of and Survival with Heart FailureThe New England Journal of Medicine, 2002